In the world of healthcare, where every claim and treatment is scrutinized, a recent development has sparked both excitement and skepticism. The story of leucovorin, an existing medication, and its sudden surge in popularity due to high-profile endorsements, is a fascinating case study in the power of influence and the challenges of evidence-based medicine. This narrative, which began with a potential breakthrough for autism spectrum disorder (ASD), raises important questions about the role of public figures in shaping medical trends and the need for rigorous scientific evaluation.
The Trump Effect and the Power of Influence
The story starts with a September announcement by President Donald Trump and Robert F. Kennedy Jr., suggesting a link between acetaminophen (Tylenol) and autism. While this claim was widely disputed by experts, it inadvertently drew attention to leucovorin, a form of folate, as a potential treatment for ASD. The impact of this announcement was particularly notable, as it led to a significant increase in the prescription rate of leucovorin among children with autism, according to a study by researchers at the University of California, San Diego.
The study, led by Joshua Rothman, analyzed prescription trends and found a 2,000% increase in leucovorin prescriptions after the Trump announcement. This surge was not isolated; it was preceded by a Fox News report in February 2025, which detailed families' experiences with the drug's potential benefits. The combination of these two events created a perfect storm, driving a significant increase in the use of leucovorin, despite the lack of strong evidence supporting its effectiveness for autism.
The Science Behind Leucovorin
Leucovorin, traditionally used to offset the side effects of cancer treatments, has also been employed to treat cerebral folate deficiency, a condition where folate cannot be transported to the brain. Unlike other forms of folate, leucovorin can reach the brain, potentially reversing this deficiency. Limited studies have suggested that children with autism may have low levels of folate in their brains, and some symptoms of cerebral folate deficiency can resemble severe autism. These tenuous connections led RFK Jr. to claim that leucovorin could benefit large numbers of children with ASD.
However, the scientific community has been cautious. The largest trial of leucovorin for autism, conducted with 77 children, was retracted due to data errors. The overall evidence supporting leucovorin for autism has always been weak, and the FDA has declined to endorse it as a treatment for ASD, citing a lack of strong evidence.
The Importance of Rigorous Research
The study by Rothman and his team is not intended to provide a definitive verdict on leucovorin's effectiveness for autism. However, it highlights the need for more research, given the significant increase in prescriptions. The team hopes that other researchers will track the long-term outcomes of families and children who have taken leucovorin for autism, emphasizing the importance of rigorous data generation for informed decision-making.
The Broader Implications
This story raises important questions about the role of public figures in shaping medical trends. While high-profile endorsements can drive public interest and potentially lead to more research, they also carry the risk of spreading misinformation. The impact of the Trump and RFK Jr. announcements underscores the need for a balanced approach, where scientific evidence is prioritized over sensational claims.
In conclusion, the case of leucovorin and its sudden popularity due to high-profile endorsements is a reminder of the delicate balance between public interest and scientific rigor. As scientists and clinicians, it is our duty to generate the rigorous data needed to help families and clinicians make informed decisions. This story serves as a call to action for more research and a reminder of the importance of evidence-based medicine in shaping healthcare trends.
